Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959852 | 1.00 | FLT3 (0.73) | FLT3PDGFRBKITKDRAKT1 | |
| SCHEMBL4960975 | 0.98 | FLT3 (0.73) | FLT3PDGFRBKITKDRAKT1 | |
| SCHEMBL5921852 | 0.95 | FLT3 (0.78) | FLT3PDGFRBKITKDRPAK1 | |
| SCHEMBL5921851 | 0.95 | FLT3 (0.78) | FLT3PDGFRBKITKDRPAK1 | |
| SCHEMBL4960587 | 0.94 | FLT3 (0.78) | FLT3PDGFRBKITKDRPAK1 | |
| SCHEMBL4963331 | 0.91 | FLT3 (0.60) | FLT3PDGFRBKITAKT1PAK1 | |
| SCHEMBL4963329 | 0.91 | FLT3 (0.60) | FLT3PDGFRBKITAKT1PAK1 | |
| SCHEMBL13956330 | 0.85 | FLT3 (1.00) | FLT3PDGFRBKIT | |
| SCHEMBL27713847 | 0.85 | FLT3 (1.00) | FLT3PDGFRBKIT | |
| SCHEMBL4959947 | 0.85 | FLT3 (0.72) | FLT3PDGFRBKITKDRAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898918-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1896029-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006135644-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135718-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TYMP | FLT3 1/4885PDGFRB 29/4885KIT 2/4885 |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, TYMP, PHKG1 | FLT3 1/4885PDGFRB 143/4885KIT 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.